![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LYPD5 |
Gene summary for LYPD5 |
![]() |
Gene information | Species | Human | Gene symbol | LYPD5 | Gene ID | 284348 |
Gene name | LY6/PLAUR domain containing 5 | |
Gene Alias | PRO4356 | |
Cytomap | 19q13.31 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6UWN5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284348 | LYPD5 | LZE24T | Human | Esophagus | ESCC | 3.22e-04 | 1.41e-01 | 0.0596 |
284348 | LYPD5 | P11T-E | Human | Esophagus | ESCC | 7.22e-04 | 2.72e-01 | 0.1426 |
284348 | LYPD5 | P16T-E | Human | Esophagus | ESCC | 1.96e-13 | 4.98e-01 | 0.1153 |
284348 | LYPD5 | P26T-E | Human | Esophagus | ESCC | 8.95e-04 | 1.42e-01 | 0.1276 |
284348 | LYPD5 | P52T-E | Human | Esophagus | ESCC | 1.28e-03 | 2.05e-01 | 0.1555 |
284348 | LYPD5 | P62T-E | Human | Esophagus | ESCC | 2.14e-04 | 1.42e-01 | 0.1302 |
284348 | LYPD5 | P75T-E | Human | Esophagus | ESCC | 1.92e-04 | 1.78e-01 | 0.1125 |
284348 | LYPD5 | P76T-E | Human | Esophagus | ESCC | 7.81e-16 | 6.70e-01 | 0.1207 |
284348 | LYPD5 | P80T-E | Human | Esophagus | ESCC | 1.21e-05 | 2.18e-01 | 0.155 |
284348 | LYPD5 | P83T-E | Human | Esophagus | ESCC | 7.81e-03 | 1.04e-01 | 0.1738 |
284348 | LYPD5 | P89T-E | Human | Esophagus | ESCC | 1.09e-08 | 5.22e-01 | 0.1752 |
284348 | LYPD5 | P130T-E | Human | Esophagus | ESCC | 6.35e-07 | 1.16e-01 | 0.1676 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LYPD5 | SNV | Missense_Mutation | c.644N>C | p.Arg215Thr | p.R215T | Q6UWN5 | protein_coding | tolerated(0.38) | benign(0.001) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
LYPD5 | SNV | Missense_Mutation | c.130N>C | p.Met44Leu | p.M44L | Q6UWN5 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-BH-A0WA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LYPD5 | SNV | Missense_Mutation | c.480N>C | p.Gln160His | p.Q160H | Q6UWN5 | protein_coding | deleterious(0.02) | probably_damaging(0.934) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
LYPD5 | SNV | Missense_Mutation | c.376N>A | p.Asp126Asn | p.D126N | Q6UWN5 | protein_coding | tolerated(1) | benign(0) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
LYPD5 | SNV | Missense_Mutation | novel | c.555N>A | p.His185Gln | p.H185Q | Q6UWN5 | protein_coding | tolerated(0.47) | benign(0.031) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
LYPD5 | SNV | Missense_Mutation | novel | c.190A>G | p.Thr64Ala | p.T64A | Q6UWN5 | protein_coding | deleterious(0.01) | benign(0.006) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LYPD5 | SNV | Missense_Mutation | c.93N>A | p.Phe31Leu | p.F31L | Q6UWN5 | protein_coding | tolerated(0.23) | benign(0.006) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
LYPD5 | SNV | Missense_Mutation | rs575058964 | c.13N>A | p.Val5Ile | p.V5I | Q6UWN5 | protein_coding | tolerated_low_confidence(0.5) | benign(0) | TCGA-CM-6676-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LYPD5 | SNV | Missense_Mutation | c.16C>T | p.Pro6Ser | p.P6S | Q6UWN5 | protein_coding | tolerated_low_confidence(0.09) | benign(0.098) | TCGA-G4-6310-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fu | SD | |
LYPD5 | SNV | Missense_Mutation | novel | c.525N>A | p.Phe175Leu | p.F175L | Q6UWN5 | protein_coding | tolerated(0.08) | benign(0.226) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |